<< Back to News

System Formulary Update
Dantrolene Products

Situation

The dantrolene products class review and formulary standardization was approved at the August 2020 System Pharmacy and Therapeutics Committee meeting.

Background

The following medications were reviewed: Dantrolene injection, dantrolene capsule, dantrolene oral suspension

Assessment/Recommendation

Go-Live: Tuesday, December 15, 2020

System P&T voted to include the following products on the UNC Health Medication Formulary:

• Dantrolene 25 mg capsule
• Dantrolene 20 mg injection (Revonto/Dantrium)
• Dantrolene 250 mg injection (Ryanodex)

Use of Ryanodex injection is restricted to initial management of malignant hyperthermia crisis (ie, Ryanodex cannot be used for post-crisis doses).

Note: Stock of these formulary products may vary at individual entities

As a result, the following products will be removed from the UNC Health Medication Formulary

• Dantrolene oral suspension
• Dantrolene capsule (50 mg, 100 mg)